Press Releases

Synthetic Biologics to Report Third Quarter Results on November 5, 2015

-- Conference Call Scheduled for Thursday, November 5, 2015 at 4:30 p.m. EST --

ROCKVILLE, Md., Oct. 19, 2015 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, intends to release its financial results for the three and nine months ended September 30, 2015 on Thursday, November 5, 2015, and to host a conference call the same day at 4:30 p.m. EST. The dial-in information for the call is as follows:

U.S. (toll free): 1-888-347-5280
International: +1 412-902-4280

Synthetic Biologics, Inc. Logo.

Participants are asked to dial in 15 minutes before the start of the call to register. The call will also be webcast over the Internet at https://www.webcaster4.com/Webcast/Page/1096/11196. An archived replay of the call will be available for approximately ninety (90) days at the same URL, https://www.webcaster4.com/Webcast/Page/1096/11196, beginning approximately one hour after the call's conclusion.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company's lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS, and in collaboration with Intrexon Corporation (NYSE: XON), a monoclonal antibody combination for the treatment of Pertussis and biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

Logo - https://photos.prnewswire.com/prnh/20130522/MM19465LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-report-third-quarter-results-on-november-5-2015-300161443.html

SOURCE Synthetic Biologics, Inc.